Inactive Instrument

IPI Legacy Liquidation Co

Equities

IMPL

US45258K1097

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 02:08:57 2024-04-05 pm EDT			5-day change	1st Jan Change
0.015 ^USD	0.00%		0.00%	-87.85%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Apr. 05	North American Morning Briefing : Investors on -2-	DJ

Motion for Joint Administration Approved for Impel Pharmaceuticals Inc.

December 20, 2023 at 11:00 pm EST

The US Bankruptcy Court granted an order for the joint administration of the Chapter 11 bankruptcy cases of Impel Pharmaceuticals Inc and its affiliate on December 21, 2023. The affiliates include Impel NeuroPharma Australia Pty Ltd. The cases would be jointly administered for administrative and procedural purposes. Impel Pharmaceuticals Inc has been designated as the lead debtor

Latest news about IPI Legacy Liquidation Co

North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
North American Morning Briefing : Investors on -2-	Apr. 05	DJ
IPI Legacy Liquidation Co Went Out of Business	Apr. 05	CI
Second Revised First Amended Liquidation Plan Approved for IPI Legacy Liquidation Co	Apr. 02	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Impel Pharmaceuticals Inc. has Changed its Name to IPI Legacy Liquidation Co	Mar. 08	CI
Combined Disclosure Statement Conditionally Approved for Impel Pharmaceuticals Inc.	Feb. 26	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Impel Pharmaceuticals Inc.	Feb. 25	CI
Impel Pharmaceuticals Inc. Announces Departure of Len Paolillo as Interim Chief Executive Officer	Feb. 14	CI
Joint Liquidation Plan and Disclosure Statement Filed by Impel Pharmaceuticals Inc.	Feb. 12	CI
An undisclosed buyer completed the acquisition of substantially all assets of Impel Pharmaceuticals Inc. for $17.5 million.	Feb. 11	CI
Motion for Asset Sale Approved for Impel Pharmaceuticals Inc.	Feb. 02	CI
Notice of Winning Bidder Filed by Impel Pharmaceuticals Inc.	Jan. 29	CI
Notice of Auction Cancellation Filed by Impel Pharmaceuticals Inc.	Jan. 26	CI
Bidding Procedure Approved for Impel Pharmaceuticals Inc.	Jan. 10	CI
Motion for Joint Administration Approved for Impel Pharmaceuticals Inc.	Dec. 20	CI
Impel Pharmaceuticals Inc. Appoints Brandon Smith as Chief Restructuring Officer	Dec. 20	CI
Impel Pharmaceuticals Files for Chapter 11 to Facilitate Sale	Dec. 20	CI
Motion for Asset Sale Filed by Impel Pharmaceuticals Inc.	Dec. 20	CI
Impel Pharmaceuticals Inc.(NasdaqGM:IMPL) dropped from S&P TMI Index	Dec. 20	CI
Impel Pharmaceuticals Inc. Filed for Bankruptcy	Dec. 19	CI
An undisclosed buyer entered into an agreement to acquire substantially all assets of Impel Pharmaceuticals Inc. for $17.5 million.	Dec. 18	CI
Motion for Joint Administration Filed by Impel Pharmaceuticals Inc.	Dec. 18	CI
Impel Pharmaceuticals Inc.(OTCPK:IMPL) dropped from NASDAQ Composite Index	Dec. 15	CI
Impel Pharmaceuticals Inc. Announces Resignation of Michael Kalb as Chief Financial Officer, Effective on December 31, 2023	Dec. 04	CI

Chart IPI Legacy Liquidation Co

Duration

Period

More charts

Company Profile

IPI Legacy Liquidation Co, formerly Impel Pharmaceuticals Inc., is not engaged in any business operations. The Company doesnât hold any assets.

Sector

Biotechnology & Medical Research

Calendar

2024-06-02 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research